Klapproth and colleagues compared QLU-C10D and PROPr scores in samples of German breast cancer patients. Although the two scales showed a strong correlation, it cannot be determined which scale had a better score in breast cancer patients because of the different measurement methods for HSU between the two scales. In addition, most studies used EQ-5D as a reference scale and validated the measurement properties of QLU-C10D. For example, two studies compared the measurement properties and impact on QALY calculation between EQ-5D-3L and C10D utility measures. Gamper and colleagues compared the relative validity of QLU-C10D and EQ-5D-3L in myelodysplastic syndrome and found that the QLU-C1OD scale had better validity and was more suitable for economic evaluation studies of MDS. However, Bulamu and colleagues compared the responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in post-esophageal cancer surgery patients and found that the measurement properties of QLU-C1OD and EQ-5D-3L scales were comparable. From existing research results, there are some differences in the conclusions obtained from comparing 5L and 3L with QLU-C10D. For example, Chen-Wei Pan and colleagues first chose EQ-5D-5L as a universal scale and compared the measurement properties of utility scores from different country-specific value sets with QLU-C10D, demonstrating that the two scales had similar convergent validity and between-group validity, and EQ-5D-5L scores may have better discriminative ability. This study validated the relevant measurement properties of QLU-C10D in Chinese cancer patients, but did not use it because at that time a utility scoring system based on the Chinese population had not been established


原文地址: http://www.cveoy.top/t/topic/h7Q2 著作权归作者所有。请勿转载和采集!

免费AI点我,无需注册和登录